The FDA has approved the first immuno-oncology combination therapy for patients with advanced renal cell carcinoma.
Browsing: Disease Area > Endocrine
In a landmark genetics study, a multi-institutional group of researchers have uncovered three distinct evolutionary paths for kidney cancer, allowing them to determine whether a tumor will be aggressive.
Eli Lilly have announced that Cyramza® has met its primary endpoint of overall survival, as well as its secondary goal of progression-free survival in late-stage liver cancer study.
To mark Rare Disease Day we recently spoke with Jonathan Wadsley (Weston Park Hospital, Sheffield, UK) about recent advancements in care for medullary thyroid cancer.
Recently at the 2018 ASCO-SIC Clinical immune-oncology symposium (CA, USA, 25-27 January) a panel discussed the science presented in a…
A phase III trial examining the use of cabozantinib for patients with previously treated advanced hepatocellular carcinoma has met its primary endpoint of overall survival.
Leading experts devise new guidelines to score thyroid nodules and avoid unnecessary surgery and aspiration numbers for benign nodules.
The largest-known study in thyroid cancer patients highlights that skeletal complications in high-risk follicular and medullary thyroid cancer patients are an indicator of poor prognosis.
In this review article from the International Journal of Endocrine Oncology, the authors explore the altered molecular pathways implicated in the development of medullary thyroid cancer and therapeutic strategies based on targeting identified signaling pathways.
In this review article read about how advancements in our understanding of the genetics are opening up new avenues for the diagnosis and management of familial pituitary adenomas.